The N-terminal fragment of chromogranin A, vasostatin-1 protects mice from acute or chronic colitis upon oral administration

Cristiano Rumio, Giuseppina F. Dusio, Barbara Colombo, Anna Gasparri, Diego Cardani, Fabrizio Marcucci, Angelo Corti

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background Vasostatin-1 (VS-1), the N-terminal fragment of chromogranin A (CgA), decreases the permeability of endothelial cells in vitro and in vivo. Aims Here, we investigated whether a similar effect could be observed also on intestinal epithelial cells (IECs) in vitro and whether VS-1 could have favorable effects on animal models of acute or chronic colitis, which are characterized by increased permeability of the intestinal epithelium. Methods In vitro, VS-1 was tested on IEC monolayers showing increased permeability, on mechanically injured IEC monolayers, and on the production of the chemokine IL-8/KC by lipopolysaccharide (LPS)-stimulated IECs. In vivo, VS-1 was tested in animal models of dextran sodium salt (DSS)-induced acute or chronic colitis. Results In vitro, VS-1 inhibited increased permeability of IECs induced by interferon-c and tumor necrosis factor-a. Moreover, VS-1 promoted healing of mechanically injured IEC monolayers, most likely through stimulation of cell migration, rather than cell proliferation. Eventually, VS-1 inhibited LPS-induced production of IL-8. In vivo, VS-1 exerted protective effects in animal models of acute or chronic colitis upon oral, but not systemic administration. Conclusions VS-1 is therapeutically active in animal models of acute or chronic, DSS-induced colitis. The mechanisms underlying this effect are likely to be multiple, and may include inhibition of enhanced intestinal permeability, repair of injured intestinal mucosae, and inhibition of the production of IL-8/KC and possibly other infammatory cytokines.

Original languageEnglish
Pages (from-to)1227-1237
Number of pages11
JournalDigestive Diseases and Sciences
Volume57
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Chromogranin A
Colitis
Oral Administration
Epithelial Cells
Permeability
Animal Models
Interleukin-8
Intestinal Mucosa
Dextrans
Lipopolysaccharides
Salts
Sodium
vasostatin I
Chemokines
Interferons
Cell Movement
Endothelial Cells
Tumor Necrosis Factor-alpha
Cell Proliferation
Cytokines

Keywords

  • Chromogranin A
  • Inflammatory bowel diseases
  • Intestinal epithelial cells
  • Vasostatin-1

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this

The N-terminal fragment of chromogranin A, vasostatin-1 protects mice from acute or chronic colitis upon oral administration. / Rumio, Cristiano; Dusio, Giuseppina F.; Colombo, Barbara; Gasparri, Anna; Cardani, Diego; Marcucci, Fabrizio; Corti, Angelo.

In: Digestive Diseases and Sciences, Vol. 57, No. 5, 05.2012, p. 1227-1237.

Research output: Contribution to journalArticle

Rumio, Cristiano ; Dusio, Giuseppina F. ; Colombo, Barbara ; Gasparri, Anna ; Cardani, Diego ; Marcucci, Fabrizio ; Corti, Angelo. / The N-terminal fragment of chromogranin A, vasostatin-1 protects mice from acute or chronic colitis upon oral administration. In: Digestive Diseases and Sciences. 2012 ; Vol. 57, No. 5. pp. 1227-1237.
@article{af7bf6fb8edc4ef9ba427d8511e7a4bd,
title = "The N-terminal fragment of chromogranin A, vasostatin-1 protects mice from acute or chronic colitis upon oral administration",
abstract = "Background Vasostatin-1 (VS-1), the N-terminal fragment of chromogranin A (CgA), decreases the permeability of endothelial cells in vitro and in vivo. Aims Here, we investigated whether a similar effect could be observed also on intestinal epithelial cells (IECs) in vitro and whether VS-1 could have favorable effects on animal models of acute or chronic colitis, which are characterized by increased permeability of the intestinal epithelium. Methods In vitro, VS-1 was tested on IEC monolayers showing increased permeability, on mechanically injured IEC monolayers, and on the production of the chemokine IL-8/KC by lipopolysaccharide (LPS)-stimulated IECs. In vivo, VS-1 was tested in animal models of dextran sodium salt (DSS)-induced acute or chronic colitis. Results In vitro, VS-1 inhibited increased permeability of IECs induced by interferon-c and tumor necrosis factor-a. Moreover, VS-1 promoted healing of mechanically injured IEC monolayers, most likely through stimulation of cell migration, rather than cell proliferation. Eventually, VS-1 inhibited LPS-induced production of IL-8. In vivo, VS-1 exerted protective effects in animal models of acute or chronic colitis upon oral, but not systemic administration. Conclusions VS-1 is therapeutically active in animal models of acute or chronic, DSS-induced colitis. The mechanisms underlying this effect are likely to be multiple, and may include inhibition of enhanced intestinal permeability, repair of injured intestinal mucosae, and inhibition of the production of IL-8/KC and possibly other infammatory cytokines.",
keywords = "Chromogranin A, Inflammatory bowel diseases, Intestinal epithelial cells, Vasostatin-1",
author = "Cristiano Rumio and Dusio, {Giuseppina F.} and Barbara Colombo and Anna Gasparri and Diego Cardani and Fabrizio Marcucci and Angelo Corti",
year = "2012",
month = "5",
doi = "10.1007/s10620-012-2031-9",
language = "English",
volume = "57",
pages = "1227--1237",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - The N-terminal fragment of chromogranin A, vasostatin-1 protects mice from acute or chronic colitis upon oral administration

AU - Rumio, Cristiano

AU - Dusio, Giuseppina F.

AU - Colombo, Barbara

AU - Gasparri, Anna

AU - Cardani, Diego

AU - Marcucci, Fabrizio

AU - Corti, Angelo

PY - 2012/5

Y1 - 2012/5

N2 - Background Vasostatin-1 (VS-1), the N-terminal fragment of chromogranin A (CgA), decreases the permeability of endothelial cells in vitro and in vivo. Aims Here, we investigated whether a similar effect could be observed also on intestinal epithelial cells (IECs) in vitro and whether VS-1 could have favorable effects on animal models of acute or chronic colitis, which are characterized by increased permeability of the intestinal epithelium. Methods In vitro, VS-1 was tested on IEC monolayers showing increased permeability, on mechanically injured IEC monolayers, and on the production of the chemokine IL-8/KC by lipopolysaccharide (LPS)-stimulated IECs. In vivo, VS-1 was tested in animal models of dextran sodium salt (DSS)-induced acute or chronic colitis. Results In vitro, VS-1 inhibited increased permeability of IECs induced by interferon-c and tumor necrosis factor-a. Moreover, VS-1 promoted healing of mechanically injured IEC monolayers, most likely through stimulation of cell migration, rather than cell proliferation. Eventually, VS-1 inhibited LPS-induced production of IL-8. In vivo, VS-1 exerted protective effects in animal models of acute or chronic colitis upon oral, but not systemic administration. Conclusions VS-1 is therapeutically active in animal models of acute or chronic, DSS-induced colitis. The mechanisms underlying this effect are likely to be multiple, and may include inhibition of enhanced intestinal permeability, repair of injured intestinal mucosae, and inhibition of the production of IL-8/KC and possibly other infammatory cytokines.

AB - Background Vasostatin-1 (VS-1), the N-terminal fragment of chromogranin A (CgA), decreases the permeability of endothelial cells in vitro and in vivo. Aims Here, we investigated whether a similar effect could be observed also on intestinal epithelial cells (IECs) in vitro and whether VS-1 could have favorable effects on animal models of acute or chronic colitis, which are characterized by increased permeability of the intestinal epithelium. Methods In vitro, VS-1 was tested on IEC monolayers showing increased permeability, on mechanically injured IEC monolayers, and on the production of the chemokine IL-8/KC by lipopolysaccharide (LPS)-stimulated IECs. In vivo, VS-1 was tested in animal models of dextran sodium salt (DSS)-induced acute or chronic colitis. Results In vitro, VS-1 inhibited increased permeability of IECs induced by interferon-c and tumor necrosis factor-a. Moreover, VS-1 promoted healing of mechanically injured IEC monolayers, most likely through stimulation of cell migration, rather than cell proliferation. Eventually, VS-1 inhibited LPS-induced production of IL-8. In vivo, VS-1 exerted protective effects in animal models of acute or chronic colitis upon oral, but not systemic administration. Conclusions VS-1 is therapeutically active in animal models of acute or chronic, DSS-induced colitis. The mechanisms underlying this effect are likely to be multiple, and may include inhibition of enhanced intestinal permeability, repair of injured intestinal mucosae, and inhibition of the production of IL-8/KC and possibly other infammatory cytokines.

KW - Chromogranin A

KW - Inflammatory bowel diseases

KW - Intestinal epithelial cells

KW - Vasostatin-1

UR - http://www.scopus.com/inward/record.url?scp=84863622207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863622207&partnerID=8YFLogxK

U2 - 10.1007/s10620-012-2031-9

DO - 10.1007/s10620-012-2031-9

M3 - Article

C2 - 22278339

AN - SCOPUS:84863622207

VL - 57

SP - 1227

EP - 1237

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 5

ER -